000257557 001__ 257557
000257557 005__ 20240309115310.0
000257557 0247_ $$2doi$$a10.3389/fneur.2023.1112312
000257557 0247_ $$2pmid$$apmid:37006483
000257557 0247_ $$2pmc$$apmc:PMC10050564
000257557 0247_ $$2altmetric$$aaltmetric:143861472
000257557 037__ $$aDZNE-2023-00437
000257557 041__ $$aEnglish
000257557 082__ $$a610
000257557 1001_ $$0P:(DE-2719)9000985$$aPerosa, Valentina$$b0$$udzne
000257557 245__ $$aImplications of quantitative susceptibility mapping at 7 Tesla MRI for microbleeds detection in cerebral small vessel disease.
000257557 260__ $$aLausanne$$bFrontiers Research Foundation$$c2023
000257557 3367_ $$2DRIVER$$aarticle
000257557 3367_ $$2DataCite$$aOutput Types/Journal article
000257557 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1690275620_16097
000257557 3367_ $$2BibTeX$$aARTICLE
000257557 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000257557 3367_ $$00$$2EndNote$$aJournal Article
000257557 520__ $$aCerebral microbleeds (MBs) are a hallmark of cerebral small vessel disease (CSVD) and can be found on T2*-weighted sequences on MRI. Quantitative susceptibility mapping (QSM) is a postprocessing method that also enables MBs identification and furthermore allows to differentiate them from calcifications.We explored the implications of using QSM at submillimeter resolution for MBs detection in CSVD.Both 3 and 7 Tesla (T) MRI were performed in elderly participants without MBs and patients with CSVD. MBs were quantified on T2*-weighted imaging and QSM. Differences in the number of MBs were assessed, and subjects were classified in CSVD subgroups or controls both on 3T T2*-weighted imaging and 7T QSM.48 participants [mean age (SD) 70.9 (8.8) years, 48% females] were included: 31 were healthy controls, 6 probable cerebral amyloid angiopathy (CAA), 9 mixed CSVD, and 2 were hypertensive arteriopathy [HA] patients. After accounting for the higher number of MBs detected at 7T QSM (Median = Mdn; Mdn7T-QSM = 2.5; Mdn3T-T2 = 0; z = 4.90; p < 0.001) and false positive MBs (6.1% calcifications), most healthy controls (80.6%) demonstrated at least one MB and more MBs were discovered in the CSVD group.Our observations suggest that QSM at submillimeter resolution improves the detection of MBs in the elderly human brain. A higher prevalence of MBs than so far known in healthy elderly was revealed.
000257557 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000257557 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x1
000257557 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000257557 650_7 $$2Other$$a7 Tesla MRI
000257557 650_7 $$2Other$$acerebral amyloid angiopathy (CAA)
000257557 650_7 $$2Other$$acerebral small vessel disease (CSVD)
000257557 650_7 $$2Other$$ahypertensive arteriopathy (HA)
000257557 650_7 $$2Other$$amicrobleeds
000257557 650_7 $$2Other$$aquantitative susceptibility mapping (QSM)
000257557 7001_ $$0P:(DE-2719)9002714$$aRotta, Johanna$$b1$$udzne
000257557 7001_ $$0P:(DE-2719)2812398$$aYakupov, Renat$$b2$$udzne
000257557 7001_ $$aKuijf, Hugo J$$b3
000257557 7001_ $$0P:(DE-2719)9000986$$aSchreiber, Frank$$b4$$udzne
000257557 7001_ $$0P:(DE-2719)2811736$$aOltmer, Jan T$$b5$$udzne
000257557 7001_ $$0P:(DE-2719)9002178$$aMattern, Hendrik$$b6$$udzne
000257557 7001_ $$0P:(DE-2719)2260426$$aHeinze, Hans-Jochen$$b7$$udzne
000257557 7001_ $$0P:(DE-2719)2000005$$aDüzel, Emrah$$b8$$udzne
000257557 7001_ $$0P:(DE-2719)2812631$$aSchreiber, Stefanie$$b9$$eLast author$$udzne
000257557 773__ $$0PERI:(DE-600)2564214-5$$a10.3389/fneur.2023.1112312$$gVol. 14, p. 1112312$$p1112312$$tFrontiers in neurology$$v14$$x1664-2295$$y2023
000257557 8564_ $$uhttps://pub.dzne.de/record/257557/files/DZNE-2023-00437.pdf$$yOpenAccess
000257557 8564_ $$uhttps://pub.dzne.de/record/257557/files/DZNE-2023-00437.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000257557 909CO $$ooai:pub.dzne.de:257557$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000257557 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9000985$$aExternal Institute$$b0$$kExtern
000257557 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002714$$aExternal Institute$$b1$$kExtern
000257557 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812398$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000257557 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000986$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000257557 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811736$$aExternal Institute$$b5$$kExtern
000257557 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002178$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000257557 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2260426$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000257557 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000005$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000257557 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812631$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000257557 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000257557 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x1
000257557 9141_ $$y2023
000257557 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-23
000257557 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-23
000257557 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000257557 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT NEUROL : 2022$$d2023-08-23
000257557 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-11T13:11:28Z
000257557 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-11T13:11:28Z
000257557 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-18
000257557 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-23
000257557 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-23
000257557 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-23
000257557 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000257557 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2021-05-11T13:11:28Z
000257557 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-18
000257557 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-18
000257557 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-23
000257557 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-18
000257557 9201_ $$0I:(DE-2719)1310010$$kAG Schreiber$$lMixed Cerebral Pathologies and Cognitive Aging$$x0
000257557 9201_ $$0I:(DE-2719)5000006$$kAG Düzel 3 ; AG Düzel ; AG Düzel$$lClinical Neurophysiology and Memory$$x1
000257557 9201_ $$0I:(DE-2719)1310005$$kAG Reymann$$lPathophysiology of Dementia$$x2
000257557 980__ $$ajournal
000257557 980__ $$aVDB
000257557 980__ $$aUNRESTRICTED
000257557 980__ $$aI:(DE-2719)1310010
000257557 980__ $$aI:(DE-2719)5000006
000257557 980__ $$aI:(DE-2719)1310005
000257557 9801_ $$aFullTexts